Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report

R. Kuint; M. Lotem; T. Neuman; E. Bekker-Milovanov; A. Abutbul; U. Laxer; N. Berkman; Z. G. Fridlender

doi:https://doi.org/10.1016/j.rmcr.2017.01.003

Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report

R. Kuint, M. Lotem, T. Neuman, E. Bekker-Milovanov, A. Abutbul, U. Laxer, N. Berkman, Z. G. Fridlender

Research output: Contribution to journal › Article › peer-review

Abstract

Pembrolizumab is a monoclonal antibody against the programmed cell death 1 (PD-1) receptor, and is widely used for the treatment of various malignancies, most commonly malignant melanoma. Here we report the first documented and pathology proven case of Organizing Pneumonia complicating treatment with Pembrolizumab. This was a man who presented with a dense lung consolidation four months following treatment with Pembrolizumab. A thorough microbiological workup was negative and his findings did not improve with broad spectrum anti-microbial treatment. Transbronchial biopsy revealed organizing pneumonia, and treatment with cortico-steroids resulted in complete resolution of clinical and radiological disease. This report highlights the importance of recognizing immune related adverse events, specifically pulmonary inflammation, in patients receiving treatment with novel immune-modulating agents.

Original language	English
Pages (from-to)	95-97
Number of pages	3
Journal	Respiratory Medicine Case Reports
Volume	20
DOIs	https://doi.org/10.1016/j.rmcr.2017.01.003
State	Published - 2017
Externally published	Yes

Keywords

Melanoma
Organizing pneumonia
Pembrolizumab

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1016/j.rmcr.2017.01.003

Cite this

@article{fc17785be098431a825c5a93f93af452,

title = "Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report",

abstract = "Pembrolizumab is a monoclonal antibody against the programmed cell death 1 (PD-1) receptor, and is widely used for the treatment of various malignancies, most commonly malignant melanoma. Here we report the first documented and pathology proven case of Organizing Pneumonia complicating treatment with Pembrolizumab. This was a man who presented with a dense lung consolidation four months following treatment with Pembrolizumab. A thorough microbiological workup was negative and his findings did not improve with broad spectrum anti-microbial treatment. Transbronchial biopsy revealed organizing pneumonia, and treatment with cortico-steroids resulted in complete resolution of clinical and radiological disease. This report highlights the importance of recognizing immune related adverse events, specifically pulmonary inflammation, in patients receiving treatment with novel immune-modulating agents.",

keywords = "Melanoma, Organizing pneumonia, Pembrolizumab",

author = "R. Kuint and M. Lotem and T. Neuman and E. Bekker-Milovanov and A. Abutbul and U. Laxer and N. Berkman and Fridlender, {Z. G.}",

note = "Publisher Copyright: {\textcopyright} 2017",

year = "2017",

doi = "https://doi.org/10.1016/j.rmcr.2017.01.003",

language = "الإنجليزيّة",

volume = "20",

pages = "95--97",

journal = "Respiratory Medicine Case Reports",

issn = "2213-0071",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report

AU - Kuint, R.

AU - Lotem, M.

AU - Neuman, T.

AU - Bekker-Milovanov, E.

AU - Abutbul, A.

AU - Laxer, U.

AU - Berkman, N.

AU - Fridlender, Z. G.

PY - 2017

Y1 - 2017

N2 - Pembrolizumab is a monoclonal antibody against the programmed cell death 1 (PD-1) receptor, and is widely used for the treatment of various malignancies, most commonly malignant melanoma. Here we report the first documented and pathology proven case of Organizing Pneumonia complicating treatment with Pembrolizumab. This was a man who presented with a dense lung consolidation four months following treatment with Pembrolizumab. A thorough microbiological workup was negative and his findings did not improve with broad spectrum anti-microbial treatment. Transbronchial biopsy revealed organizing pneumonia, and treatment with cortico-steroids resulted in complete resolution of clinical and radiological disease. This report highlights the importance of recognizing immune related adverse events, specifically pulmonary inflammation, in patients receiving treatment with novel immune-modulating agents.

AB - Pembrolizumab is a monoclonal antibody against the programmed cell death 1 (PD-1) receptor, and is widely used for the treatment of various malignancies, most commonly malignant melanoma. Here we report the first documented and pathology proven case of Organizing Pneumonia complicating treatment with Pembrolizumab. This was a man who presented with a dense lung consolidation four months following treatment with Pembrolizumab. A thorough microbiological workup was negative and his findings did not improve with broad spectrum anti-microbial treatment. Transbronchial biopsy revealed organizing pneumonia, and treatment with cortico-steroids resulted in complete resolution of clinical and radiological disease. This report highlights the importance of recognizing immune related adverse events, specifically pulmonary inflammation, in patients receiving treatment with novel immune-modulating agents.

KW - Melanoma

KW - Organizing pneumonia

KW - Pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85009438154&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.rmcr.2017.01.003

DO - https://doi.org/10.1016/j.rmcr.2017.01.003

M3 - مقالة

SN - 2213-0071

VL - 20

SP - 95

EP - 97

JO - Respiratory Medicine Case Reports

JF - Respiratory Medicine Case Reports

ER -

Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report

Abstract

Keywords

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this